Opthea Limited (AU:OPT) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Opthea Limited has achieved significant milestones in its quest to enhance treatment for wet age-related macular degeneration, including the successful enrollment of nearly 2,000 patients in pivotal trials and raising over $236 million in funding. The company also strengthened its leadership team and announced key board changes, as it prepares for upcoming data readouts. With these advancements, Opthea is poised to transform patient care and deliver shareholder value.
For further insights into AU:OPT stock, check out TipRanks’ Stock Analysis page.
